Shruti Agashe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shruti Agashe has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Gregory D. Cascino
Department of Neurology Mayo Clinic Rochester Minnesota USA
3 shared publicationsJamie J. Van Gompel
Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA
3 shared publications- Barry E. Gidal
Division of Pharmacy Practice and Translational Research, University of Wisconsin, School of Pharmacy, Madison
2 shared publications Benjamin H. Brinkmann
Department of Neurology, Mayo Clinic, Rochester, MN, USA
2 shared publicationsBrian N. Lundstrom
Department of Neurology, Mayo Clinic, Rochester, MN, USA
2 shared publications- Gregory A. Worrell
Department of Neurology Mayo Clinic Rochester Minnesota USA
2 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by SAGE Publications in Epilepsy Currents
- Vol. 26 (5) , 403-405
Starting Young: Responsive Neurostimulation in Children
Responsive Neurostimulation in Children, Adolescents, and Young Adults-Longitudinal Effectiveness and Safety Lee ST, Patel S, Karakas C, Houck K, Trandafir C, McGinley MJ, Mohanty D, Riviello JJ, Weiner HL, Curry D, Ali I. Neurotherapeutics . 2026 Mar 19;23(2):e00865. doi: 10.1016/j.neurot.2026.e00865. Epub ahead of print. PMID: 41863185; PMCID: PMC13010426 Drug-resistant epilepsy (DRE) remains challenging to treat, and seizure control often fluctuates over time. Responsive neurostimulation (RNS) is increasingly used in pediatric and young adult populations, yet long-term effectiveness and safety data are limited. We evaluated longitudinal seizure control trajectories and safety of RNS in children, adolescents, and young adults treated at our center. Seizure frequency was assessed at approximately 6-month intervals from serial follow-up visits through the most recent follow-up, with each sampled visit categorized by ≥50% (all-responder, AR) or ≥90% (super-responder, SR) seizure reduction. We examined the persistence and durability of seizure control and used recurrent-event regression to identify clinical modifiers of sustained response. Responder rates improved over time, with 57% and 75% of patients achieving AR status at 24 and 47 mean months post-implantation, respectively; corresponding SR rates were 22% and 33%. Once achieved, seizure control was typically maintained: the probability of remaining an AR for 24 months was 70%, and the median proportion of follow-up with sustained response exceeded 85% across age groups. Concurrent epilepsy surgery favored maintenance of AR status (HR 1.83, p = 0.02), while syndrome-related epilepsies reduced the likelihood of sustained SR status (HR 0.30, p = 0.03). Age at implantation and responder status at 24 months both associated with long-term seizure control. Serious (0.032 events/person-year) and non-serious (0.038 events/person-year) adverse effects were infrequent. RNS provided durable benefit for most, though not all, patients, reflecting the dynamic nature of seizure control. The favorable effectiveness and safety profile support use of RNS in young patients with DRE.
- 27 July 2026
- Published by SAGE Publications in Epilepsy Currents
- Vol. 26 (5) , 403-405
Open AccessStarting Young: Responsive Neurostimulation in Children
Responsive Neurostimulation in Children, Adolescents, and Young Adults-Longitudinal Effectiveness and Safety Lee ST, Patel S, Karakas C, Houck K, Trandafir C, McGinley MJ, Mohanty D, Riviello JJ, Weiner HL, Curry D, Ali I. Neurotherapeutics . 2026 Mar 19;23(2):e00865. doi: 10.1016/j.neurot.2026.e00865. Epub ahead of print. PMID: 41863185; PMCID: PMC13010426 Drug-resistant epilepsy (DRE) remains challenging to treat, and seizure control often fluctuates over time. Responsive neurostimulation (RNS) is increasingly used in pediatric and young adult populations, yet long-term effectiveness and safety data are limited. We evaluated longitudinal seizure control trajectories and safety of RNS in children, adolescents, and young adults treated at our center. Seizure frequency was assessed at approximately 6-month intervals from serial follow-up visits through the most recent follow-up, with each sampled visit categorized by ≥50% (all-responder, AR) or ≥90% (super-responder, SR) seizure reduction. We examined the persistence and durability of seizure control and used recurrent-event regression to identify clinical modifiers of sustained response. Responder rates improved over time, with 57% and 75% of patients achieving AR status at 24 and 47 mean months post-implantation, respectively; corresponding SR rates were 22% and 33%. Once achieved, seizure control was typically maintained: the probability of remaining an AR for 24 months was 70%, and the median proportion of follow-up with sustained response exceeded 85% across age groups. Concurrent epilepsy surgery favored maintenance of AR status (HR 1.83, p = 0.02), while syndrome-related epilepsies reduced the likelihood of sustained SR status (HR 0.30, p = 0.03). Age at implantation and responder status at 24 months both associated with long-term seizure control. Serious (0.032 events/person-year) and non-serious (0.038 events/person-year) adverse effects were infrequent. RNS provided durable benefit for most, though not all, patients, reflecting the dynamic nature of seizure control. The favorable effectiveness and safety profile support use of RNS in young patients with DRE.
- Open Access
Artificial intelligence for adaptive neuromodulation in drug‐resistant epilepsy
Drug‐resistant epilepsy (DRE) affects nearly one third of people with epilepsy and is associated with substantial cognitive, psychiatric, and mortality burdens. For patients who are not candidates for resection or laser interstitial thermal therapy, neuromodulation therapies such as vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation offer an important and established therapeutic option that can provide substantial, often life‐changing benefits, although clinical response varies widely and typically requires prolonged, iterative optimization. Epilepsy is increasingly understood as a disorder of distributed and dynamic brain networks, in which seizure generation, propagation, and termination reflect interactions among connected regions that evolve over time. In this setting, improving neuromodulation requires precise and patient‐specific decisions across the treatment workflow. This perspective reframes neuromodulation as a control problem organized around four interdependent clinical questions: who is most likely to benefit, where to deliver stimulation within an individual's epileptic network, when to apply stimulation relative to evolving seizure risk, and how to configure and adapt stimulation parameters over time. Artificial intelligence (AI) may provide a unifying framework for addressing these questions in a personalized and data‐driven manner. AI‐guided response prediction could estimate the likelihood of benefit before implantation. AI‐driven network analyses could identify optimal stimulation targets based on circuit influence rather than seizure onset alone. AI‐based state estimation could enable continuous forecasting of seizure risk across short‐term, circadian, and multidien timescales, supporting stimulation during periods of rising vulnerability rather than solely in response to detected seizures. Also, AI‐enabled adaptive control could optimize stimulation parameters through state‐dependent strategies that balance efficacy, safety, tolerability, and energy constraints as brain dynamics evolve. This review synthesizes biological, clinical, and computational advances to outline a roadmap for safe, interpretable, and individualized AI‐guided neuromodulation in DRE.
Open AccessArtificial intelligence for adaptive neuromodulation in drug‐resistant epilepsy
Drug‐resistant epilepsy (DRE) affects nearly one third of people with epilepsy and is associated with substantial cognitive, psychiatric, and mortality burdens. For patients who are not candidates for resection or laser interstitial thermal therapy, neuromodulation therapies such as vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation offer an important and established therapeutic option that can provide substantial, often life‐changing benefits, although clinical response varies widely and typically requires prolonged, iterative optimization. Epilepsy is increasingly understood as a disorder of distributed and dynamic brain networks, in which seizure generation, propagation, and termination reflect interactions among connected regions that evolve over time. In this setting, improving neuromodulation requires precise and patient‐specific decisions across the treatment workflow. This perspective reframes neuromodulation as a control problem organized around four interdependent clinical questions: who is most likely to benefit, where to deliver stimulation within an individual's epileptic network, when to apply stimulation relative to evolving seizure risk, and how to configure and adapt stimulation parameters over time. Artificial intelligence (AI) may provide a unifying framework for addressing these questions in a personalized and data‐driven manner. AI‐guided response prediction could estimate the likelihood of benefit before implantation. AI‐driven network analyses could identify optimal stimulation targets based on circuit influence rather than seizure onset alone. AI‐based state estimation could enable continuous forecasting of seizure risk across short‐term, circadian, and multidien timescales, supporting stimulation during periods of rising vulnerability rather than solely in response to detected seizures. Also, AI‐enabled adaptive control could optimize stimulation parameters through state‐dependent strategies that balance efficacy, safety, tolerability, and energy constraints as brain dynamics evolve. This review synthesizes biological, clinical, and computational advances to outline a roadmap for safe, interpretable, and individualized AI‐guided neuromodulation in DRE.
- Open Access
- 9 December 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 26 (2) , 136-138
From Seconds to Seasons: First-in-Human Insights from a Chronic Subscalp EEG System
Objective: Patient self-report is known to be an inaccurate reflection of true seizure frequency in persons with epilepsy. The current study aimed to assess the safety and performance of the Minder system, a bilateral subscalp electroencephalographic (EEG) acquisition system for continuous long-term EEG recording. Methods: This prospective, multicenter first-in-human study enrolled adult patients with focal or generalized epilepsy and at least 2 seizures per month. The primary outcome was adverse events (AEs) in the first 6 months of implantation. Secondary analyses determined whether normal neurophysiological signals, interictal discharges, and seizures seen on scalp video EEG monitoring were identifiable on subscalp recordings, and signals were rated for clarity on subscalp and 2-channel scalp EEG recordings (1 = not recognizable, 5 = clear). Subscalp data were reviewed in relation to events reported in 6-month seizure diaries. Results: Twenty-six subjects were implanted between November 2019 and July 2023. No serious device- or implant procedure-related AEs were reported. The most common device-related AEs were mild or moderate postsurgical pain, headache, or scalp pain/paresthesia (9/26, 35%). All sleep spindles, chewing artifacts, interictal discharges, and electrographic seizures observed on scalp recordings (25 seizures from 8 patients) were identified on subscalp recordings and given higher clarity ratings compared to 2-channel scalp recordings (median seizure clarity rating was 3 for both scalp and subscalp EEG, range = 1-5, P = .0025). Subscalp recordings captured seizures from diverse seizure focus locations, including frontal and mesial temporal seizure foci and hypothalamic hamartoma. Bilateral recording revealed clinically relevant findings not possible with unilateral recordings (6/26 patients, 23%). Findings of potential clinical utility were identified on manual review of 6-month recordings in most patients (23/26, 88%). Significance: This study demonstrates the safety and performance of the Minder bilateral subscalp EEG acquisition system for long-term seizure monitoring in patients with epilepsy. Bilateral hemisphere coverage captured seizures in a diverse patient group and permitted lateralization of events.
- 9 December 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 26 (2) , 136-138
Open AccessFrom Seconds to Seasons: First-in-Human Insights from a Chronic Subscalp EEG System
Objective: Patient self-report is known to be an inaccurate reflection of true seizure frequency in persons with epilepsy. The current study aimed to assess the safety and performance of the Minder system, a bilateral subscalp electroencephalographic (EEG) acquisition system for continuous long-term EEG recording. Methods: This prospective, multicenter first-in-human study enrolled adult patients with focal or generalized epilepsy and at least 2 seizures per month. The primary outcome was adverse events (AEs) in the first 6 months of implantation. Secondary analyses determined whether normal neurophysiological signals, interictal discharges, and seizures seen on scalp video EEG monitoring were identifiable on subscalp recordings, and signals were rated for clarity on subscalp and 2-channel scalp EEG recordings (1 = not recognizable, 5 = clear). Subscalp data were reviewed in relation to events reported in 6-month seizure diaries. Results: Twenty-six subjects were implanted between November 2019 and July 2023. No serious device- or implant procedure-related AEs were reported. The most common device-related AEs were mild or moderate postsurgical pain, headache, or scalp pain/paresthesia (9/26, 35%). All sleep spindles, chewing artifacts, interictal discharges, and electrographic seizures observed on scalp recordings (25 seizures from 8 patients) were identified on subscalp recordings and given higher clarity ratings compared to 2-channel scalp recordings (median seizure clarity rating was 3 for both scalp and subscalp EEG, range = 1-5, P = .0025). Subscalp recordings captured seizures from diverse seizure focus locations, including frontal and mesial temporal seizure foci and hypothalamic hamartoma. Bilateral recording revealed clinically relevant findings not possible with unilateral recordings (6/26 patients, 23%). Findings of potential clinical utility were identified on manual review of 6-month recordings in most patients (23/26, 88%). Significance: This study demonstrates the safety and performance of the Minder bilateral subscalp EEG acquisition system for long-term seizure monitoring in patients with epilepsy. Bilateral hemisphere coverage captured seizures in a diverse patient group and permitted lateralization of events.
- Open Access
- 12 November 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 26 (1) , 31-33
Tuning Into the Centromedian: The Metronome of Generalized Epilepsy
Chronic Thalamic Recordings for Idiopathic Generalized Epilepsy and Lennox–Gastaut Syndrome: Ictal and Interictal Electrophysiological Findings Bullinger KL, Crudele AN, Morrell MJ, Johnson L. Epilepsia Open . 2025; 10: 1099-1110. https://doi.org/10.1002/epi4.70069 Objective: To leverage RNS ® System chronic thalamic EEG recordings to compare ictal and interictal thalamic electrophysiology in idiopathic generalized epilepsy (IGE) and Lennox–Gastaut Syndrome (LGS). Methods: As part of ongoing clinical trials in IGE and LGS, intracranial EEG data were acquired from the centromedian nucleus (CM) bilaterally. Ictal recordings were evaluated by trained epileptologists for preictal and ictal onset patterns. The number of detections and the frequency characteristics of interictal and ictal activity were compared across groups. Results: Ictal activity was clearly observed in the CM in IGE and LGS. Detections of interictal epileptiform activity and electrographic seizures were more frequent in LGS. Interictal frequency peaks had similar characteristics across cohorts, although low frequencies were more frequent in LGS. All participants with LGS had 2 or more ictal onset patterns. Most often, onset patterns were similar bilaterally. However, 20% of participants had some seizures with different onset patterns on the right and left, and 50% had some seizures that were unilateral. Low voltage fast activity was the most common onset pattern, followed by bursts of polyspikes and then rhythmic <13 Hz activity. In IGE participants, rhythmic <13 Hz activity was the most common ictal onset pattern; spike and wave was the next most common onset pattern. Two additional onset types were observed: polyspike onset and high amplitude delta followed by low amplitude fast activity onset. Onset patterns were generally consistent within an individual; only 20% of participants had multiple seizure onset types. Significance: Differences in interictal background are consistent with the known phenotypes of IGE and LGS. Furthermore, CM recordings of ictal activity in both cohorts support the feasibility of closed-loop stimulation, with detection settings programmed according to each individual's seizure onset pattern.
- 12 November 2025
- Published by SAGE Publications in Epilepsy Currents
- Vol. 26 (1) , 31-33
Open AccessTuning Into the Centromedian: The Metronome of Generalized Epilepsy
Chronic Thalamic Recordings for Idiopathic Generalized Epilepsy and Lennox–Gastaut Syndrome: Ictal and Interictal Electrophysiological Findings Bullinger KL, Crudele AN, Morrell MJ, Johnson L. Epilepsia Open . 2025; 10: 1099-1110. https://doi.org/10.1002/epi4.70069 Objective: To leverage RNS ® System chronic thalamic EEG recordings to compare ictal and interictal thalamic electrophysiology in idiopathic generalized epilepsy (IGE) and Lennox–Gastaut Syndrome (LGS). Methods: As part of ongoing clinical trials in IGE and LGS, intracranial EEG data were acquired from the centromedian nucleus (CM) bilaterally. Ictal recordings were evaluated by trained epileptologists for preictal and ictal onset patterns. The number of detections and the frequency characteristics of interictal and ictal activity were compared across groups. Results: Ictal activity was clearly observed in the CM in IGE and LGS. Detections of interictal epileptiform activity and electrographic seizures were more frequent in LGS. Interictal frequency peaks had similar characteristics across cohorts, although low frequencies were more frequent in LGS. All participants with LGS had 2 or more ictal onset patterns. Most often, onset patterns were similar bilaterally. However, 20% of participants had some seizures with different onset patterns on the right and left, and 50% had some seizures that were unilateral. Low voltage fast activity was the most common onset pattern, followed by bursts of polyspikes and then rhythmic <13 Hz activity. In IGE participants, rhythmic <13 Hz activity was the most common ictal onset pattern; spike and wave was the next most common onset pattern. Two additional onset types were observed: polyspike onset and high amplitude delta followed by low amplitude fast activity onset. Onset patterns were generally consistent within an individual; only 20% of participants had multiple seizure onset types. Significance: Differences in interictal background are consistent with the known phenotypes of IGE and LGS. Furthermore, CM recordings of ictal activity in both cohorts support the feasibility of closed-loop stimulation, with detection settings programmed according to each individual's seizure onset pattern.
- 16 July 2025
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 42 (6) , 479-480
Editorial: Personalizing Intracranial Neuromodulation in Epilepsy
- 16 July 2025
- Published by Wolters Kluwer Health in Journal Of Clinical Neurophysiology
- Vol. 42 (6) , 479-480
Editorial: Personalizing Intracranial Neuromodulation in Epilepsy
Focal to bilateral tonic–clonic seizures in newly diagnosed focal epilepsy
Presence of focal to bilateral tonic–clonic seizures (FBTCS) in focal epilepsy is associated with increased morbidity and mortality. Risk factors for FBTCS are poorly understood, and little is known regarding FBTCS recurrence after treatment initiation. This study aimed to investigate factors related to FBTCS in newly diagnosed focal epilepsy and their recurrence after starting antiseizure medications (ASMs) in the Human Epilepsy Project (HEP) cohort. HEP was an international, prospective cohort study that enrolled people with newly diagnosed focal epilepsy within 4 months of treatment initiation and followed them for up to 6 years. Baseline characteristics, treatment choices, and seizure outcomes were collected. Descriptive and inferential statistical analysis was conducted to assess the differences between study participants who had FBTCS and those who never experienced FBTCS. A total of 443 participants were included in this analysis; 77% (n = 342) had FBTCS at some point prior to or within the study period. In participants with FBTCS, regardless of initial seizure type, diagnosis was mostly made after FBTCS (335/342, 98%). After treatment initiation, FBTCS did not recur in 57% (n = 194/342) of cases. A higher number of total pretreatment seizures (median = 16 vs. 11, p = .048, Mann–Whitney U‐test), predominantly focal aware seizures (FAS) or focal impaired awareness seizures (FIAS; median = 15 vs. 10, p = .049, Mann Whitney U‐test), was associated with no recurrence in FBTCS after treatment initiation. Of 108 participants without FBTCS prior to treatment, only seven (6%) developed FBTCS after treatment initiation. There was no significant difference in choice of initial ASM class (levetiracetam vs. sodium channel blockers) between participants who experienced FBTCS and those who did not. This study highlights the significance of FBTCS among individuals with newly diagnosed focal epilepsy. The majority of participants who experienced FBTCS were diagnosed with epilepsy after experiencing their first FBTCS despite preceding FAS/FIAS. The more frequent FAS/FIAS in participants whose FBTCS resolved may be a characteristic of their epilepsy.
Focal to bilateral tonic–clonic seizures in newly diagnosed focal epilepsy
Presence of focal to bilateral tonic–clonic seizures (FBTCS) in focal epilepsy is associated with increased morbidity and mortality. Risk factors for FBTCS are poorly understood, and little is known regarding FBTCS recurrence after treatment initiation. This study aimed to investigate factors related to FBTCS in newly diagnosed focal epilepsy and their recurrence after starting antiseizure medications (ASMs) in the Human Epilepsy Project (HEP) cohort. HEP was an international, prospective cohort study that enrolled people with newly diagnosed focal epilepsy within 4 months of treatment initiation and followed them for up to 6 years. Baseline characteristics, treatment choices, and seizure outcomes were collected. Descriptive and inferential statistical analysis was conducted to assess the differences between study participants who had FBTCS and those who never experienced FBTCS. A total of 443 participants were included in this analysis; 77% (n = 342) had FBTCS at some point prior to or within the study period. In participants with FBTCS, regardless of initial seizure type, diagnosis was mostly made after FBTCS (335/342, 98%). After treatment initiation, FBTCS did not recur in 57% (n = 194/342) of cases. A higher number of total pretreatment seizures (median = 16 vs. 11, p = .048, Mann–Whitney U‐test), predominantly focal aware seizures (FAS) or focal impaired awareness seizures (FIAS; median = 15 vs. 10, p = .049, Mann Whitney U‐test), was associated with no recurrence in FBTCS after treatment initiation. Of 108 participants without FBTCS prior to treatment, only seven (6%) developed FBTCS after treatment initiation. There was no significant difference in choice of initial ASM class (levetiracetam vs. sodium channel blockers) between participants who experienced FBTCS and those who did not. This study highlights the significance of FBTCS among individuals with newly diagnosed focal epilepsy. The majority of participants who experienced FBTCS were diagnosed with epilepsy after experiencing their first FBTCS despite preceding FAS/FIAS. The more frequent FAS/FIAS in participants whose FBTCS resolved may be a characteristic of their epilepsy.
- Open Access
- 18 December 2024
- Published by SAGE Publications in Epilepsy Currents
- Vol. 25 (2) , 113-115
MORE Than Meets the Eye: The Evolving Landscape of DBS in Epilepsy
Long-Term Evaluation of Anterior Thalamic Deep Brain Stimulation for Epilepsy in the European MORE Registry Kaufmann E, Peltola J, Colon AJ, Lehtimäki K, Majtanik M, Mai JK, Bóné B, Bentes C, Coenen V, Gil-Nagel A, Goncalves-Ferreira AJ, Ryvlin P, Taylor R, Brionne TC, Gielen F, Song S, Boon P; MORE study group. Epilepsia. 2024;65(8):2438-2458. doi: 10.1111/epi.18003 Objective: Short-term outcomes of deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) were reported for people with drug-resistant focal epilepsy (PwE). Because long-term data are still scarce, the Medtronic Registry for Epilepsy (MORE) evaluated clinical routine application of ANT-DBS. Methods: In this multicenter registry, PwE with ANT-DBS were followed up for safety, efficacy, and battery longevity. Follow up ended after 5 years or upon study closure. Clinical characteristics and stimulation settings were compared between PwE with no benefit, improvers, and responders, that is, PwE with average monthly seizure frequency reduction rates of ≥50%. Results: Of 170 eligible PwE, 104, 62, and 49 completed the 3-, 4-, and 5-year follow up, respectively. Most discontinuations (68%) were due to planned study closure as follow up beyond 2 years was optional. The 5-year follow-up cohort had a median seizure frequency reduction from 16 per month at baseline to 7.9 per month at 5-year follow up ( P < .001), with most-pronounced effects on focal-to-bilateral tonic–clonic seizures (n = 15, 77% reduction, P = .008). At last follow up (median 3.5 years), 41% (69/170) of PwE were responders. Unifocal epilepsy ( P = .035) and a negative history of epilepsy surgery ( P = .002) were associated with larger average monthly seizure frequency reductions. Stimulation settings did not differ between response groups. In 179 implanted PwE, DBS-related adverse events (AEs, n = 225) and serious AEs (n = 75) included deterioration in epilepsy or seizure frequency/severity/type (33; 14 serious), memory/cognitive impairment (29; 3 serious), and depression (13; 4 serious). Five deaths occurred (none were ANT-DBS related). Most AEs (76.3%) manifested within the first 2 years after implantation. Activa PC depletion (n = 37) occurred on average after 45 months. Significance: MORE provides further evidence for the long-term application of ANT-DBS in clinical routine practice. Although clinical benefits increased over time, side effects occurred mainly during the first 2 years. Identified outcome modifiers can help inform PwE selection and management.
- 18 December 2024
- Published by SAGE Publications in Epilepsy Currents
- Vol. 25 (2) , 113-115
Open AccessMORE Than Meets the Eye: The Evolving Landscape of DBS in Epilepsy
Long-Term Evaluation of Anterior Thalamic Deep Brain Stimulation for Epilepsy in the European MORE Registry Kaufmann E, Peltola J, Colon AJ, Lehtimäki K, Majtanik M, Mai JK, Bóné B, Bentes C, Coenen V, Gil-Nagel A, Goncalves-Ferreira AJ, Ryvlin P, Taylor R, Brionne TC, Gielen F, Song S, Boon P; MORE study group. Epilepsia. 2024;65(8):2438-2458. doi: 10.1111/epi.18003 Objective: Short-term outcomes of deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) were reported for people with drug-resistant focal epilepsy (PwE). Because long-term data are still scarce, the Medtronic Registry for Epilepsy (MORE) evaluated clinical routine application of ANT-DBS. Methods: In this multicenter registry, PwE with ANT-DBS were followed up for safety, efficacy, and battery longevity. Follow up ended after 5 years or upon study closure. Clinical characteristics and stimulation settings were compared between PwE with no benefit, improvers, and responders, that is, PwE with average monthly seizure frequency reduction rates of ≥50%. Results: Of 170 eligible PwE, 104, 62, and 49 completed the 3-, 4-, and 5-year follow up, respectively. Most discontinuations (68%) were due to planned study closure as follow up beyond 2 years was optional. The 5-year follow-up cohort had a median seizure frequency reduction from 16 per month at baseline to 7.9 per month at 5-year follow up ( P < .001), with most-pronounced effects on focal-to-bilateral tonic–clonic seizures (n = 15, 77% reduction, P = .008). At last follow up (median 3.5 years), 41% (69/170) of PwE were responders. Unifocal epilepsy ( P = .035) and a negative history of epilepsy surgery ( P = .002) were associated with larger average monthly seizure frequency reductions. Stimulation settings did not differ between response groups. In 179 implanted PwE, DBS-related adverse events (AEs, n = 225) and serious AEs (n = 75) included deterioration in epilepsy or seizure frequency/severity/type (33; 14 serious), memory/cognitive impairment (29; 3 serious), and depression (13; 4 serious). Five deaths occurred (none were ANT-DBS related). Most AEs (76.3%) manifested within the first 2 years after implantation. Activa PC depletion (n = 37) occurred on average after 45 months. Significance: MORE provides further evidence for the long-term application of ANT-DBS in clinical routine practice. Although clinical benefits increased over time, side effects occurred mainly during the first 2 years. Identified outcome modifiers can help inform PwE selection and management.
- 21 September 2024
- Published by Wiley in Epileptic Disorders
- Vol. 26 (6) , 868-874
Sleep‐related hypermotor seizures originating from the occipital lobe
We present two unique cases of sleep‐related hypermotor epilepsy (SHE) originating from the occipital lobe. Patients with sleep‐related seizures and drug‐resistant occipital lobe epilepsy were identified from the ANPHY lab stereo‐electroencephalography (SEEG) research database at the Duke Comprehensive Epilepsy Center. We identified two young females with frequent sleep‐related focal seizures and occasional focal to bilateral tonic clonic seizures characterized by hypermotor movements. During wakefulness, the semiology also involved an elementary visual aura. They meet the 2016 diagnostic criteria for SHE, and SEEG monitoring with cortical stimulation mapping identified an epileptogenic zone (EZ) within the occipital lobe, with most seizures occurring out of NREM 2 sleep. Responsive neurostimulation devices were implanted, which indicated a trend for event detections in nocturnal periods. Extrafrontal SHE has characteristically been described in the temporal, insular‐opercular, and parietal lobes. Here, we demonstrate using SEEG‐confirmed EZ identification, that SHE can also originate in the occipital lobe. In patients with sleep‐related seizures and hypermotor behavior, occipital lobe seizures thus should not be excluded from the differential diagnosis. Key in identifying this rare localization is non‐frontal aura semiology and delay to motor symptoms, which may be supported by a visual field deficit and structural MRI abnormality.
- 21 September 2024
- Published by Wiley in Epileptic Disorders
- Vol. 26 (6) , 868-874
Sleep‐related hypermotor seizures originating from the occipital lobe
We present two unique cases of sleep‐related hypermotor epilepsy (SHE) originating from the occipital lobe. Patients with sleep‐related seizures and drug‐resistant occipital lobe epilepsy were identified from the ANPHY lab stereo‐electroencephalography (SEEG) research database at the Duke Comprehensive Epilepsy Center. We identified two young females with frequent sleep‐related focal seizures and occasional focal to bilateral tonic clonic seizures characterized by hypermotor movements. During wakefulness, the semiology also involved an elementary visual aura. They meet the 2016 diagnostic criteria for SHE, and SEEG monitoring with cortical stimulation mapping identified an epileptogenic zone (EZ) within the occipital lobe, with most seizures occurring out of NREM 2 sleep. Responsive neurostimulation devices were implanted, which indicated a trend for event detections in nocturnal periods. Extrafrontal SHE has characteristically been described in the temporal, insular‐opercular, and parietal lobes. Here, we demonstrate using SEEG‐confirmed EZ identification, that SHE can also originate in the occipital lobe. In patients with sleep‐related seizures and hypermotor behavior, occipital lobe seizures thus should not be excluded from the differential diagnosis. Key in identifying this rare localization is non‐frontal aura semiology and delay to motor symptoms, which may be supported by a visual field deficit and structural MRI abnormality.
Centromedian thalamic deep brain stimulation for idiopathic generalized epilepsy: Connectivity and target optimization
There are limited treatment options for individuals with drug‐resistant idiopathic generalized epilepsy (IGE). Small, limited case series suggest that centromedian thalamus deep brain stimulation (CM‐DBS) may be an effective treatment option. The optimal CM‐DBS target for IGE is underexamined. Here, we present a retrospective analysis of CM‐DBS targeting and efficacy for five patients with drug‐resistant IGE. Volume of tissue activated (VTA) overlap with CM nucleus was performed using an open‐source toolbox. Median follow‐up time was 13 months. Median convulsive seizure frequency reduction was 66%. One patient had only absence seizures, with >99% reduction in absence seizure frequency. Four patients had electrode contacts positioned within the CM nucleus target, all of whom had >50% reduction in primary semiology seizure, with 85% median seizure reduction (p = .004, paired‐sample t test). Volumetric “sweet‐spot” mapping revealed that best outcomes were correlated with stimulation of the middle ventral CM nucleus. Connectivity strength between the sweet‐spot region and central peri‐Rolandic cortex was increased significantly relative to other cortical regions (p = 8.6 × 10−4, Mann–Whitney U test). Our findings indicate that CM‐DBS can be an effective treatment for patients with IGE, highlight the importance of accurate targeting and targeting analysis, and within the context of prior work, suggest that ideal CM‐DBS targets may be syndrome specific.
Centromedian thalamic deep brain stimulation for idiopathic generalized epilepsy: Connectivity and target optimization
There are limited treatment options for individuals with drug‐resistant idiopathic generalized epilepsy (IGE). Small, limited case series suggest that centromedian thalamus deep brain stimulation (CM‐DBS) may be an effective treatment option. The optimal CM‐DBS target for IGE is underexamined. Here, we present a retrospective analysis of CM‐DBS targeting and efficacy for five patients with drug‐resistant IGE. Volume of tissue activated (VTA) overlap with CM nucleus was performed using an open‐source toolbox. Median follow‐up time was 13 months. Median convulsive seizure frequency reduction was 66%. One patient had only absence seizures, with >99% reduction in absence seizure frequency. Four patients had electrode contacts positioned within the CM nucleus target, all of whom had >50% reduction in primary semiology seizure, with 85% median seizure reduction (p = .004, paired‐sample t test). Volumetric “sweet‐spot” mapping revealed that best outcomes were correlated with stimulation of the middle ventral CM nucleus. Connectivity strength between the sweet‐spot region and central peri‐Rolandic cortex was increased significantly relative to other cortical regions (p = 8.6 × 10−4, Mann–Whitney U test). Our findings indicate that CM‐DBS can be an effective treatment for patients with IGE, highlight the importance of accurate targeting and targeting analysis, and within the context of prior work, suggest that ideal CM‐DBS targets may be syndrome specific.
- Open Access
- 9 May 2024
- Published by SAGE Publications in Epilepsy Currents
- Vol. 24 (4) , 254-255
Stereo-EEG Planning: Hitting the Target but Missing the Point?
Optimization of Patient-Specific Stereo-EEG Recording Sensitivity Dessert GE, Thio BJ, Grill WM. Brain Commun . 2023;5(6):fcad304. doi: 10.1093/braincomms/fcad304 . PMID: 38025277 ; PMCID: PMC10655844 Stereo-EEG is a minimally invasive technique used to localize the origin of epileptic activity (the epileptogenic zone) in patients with drug-resistant epilepsy. However, current stereo-EEG trajectory planning methods are agnostic to the spatial recording sensitivity of implanted electrodes. In this study, we used image-based patient-specific computational models to design optimized stereo-EEG electrode configurations. Patient-specific optimized electrode configurations exhibited substantially higher recording sensitivity than clinically implanted configurations, and this may lead to a more accurate delineation of the epileptogenic zone. The optimized configurations also achieved equally good or better recording sensitivity with fewer electrodes compared with clinically implanted configurations, and this may reduce the risk for complications, including intracranial hemorrhage. This approach improves localization of the epileptogenic zone by transforming the clinical use of stereo-EEG from a discrete ad hoc sampling to an intelligent mapping of the regions of interest.
- 9 May 2024
- Published by SAGE Publications in Epilepsy Currents
- Vol. 24 (4) , 254-255
Open AccessStereo-EEG Planning: Hitting the Target but Missing the Point?
Optimization of Patient-Specific Stereo-EEG Recording Sensitivity Dessert GE, Thio BJ, Grill WM. Brain Commun . 2023;5(6):fcad304. doi: 10.1093/braincomms/fcad304 . PMID: 38025277 ; PMCID: PMC10655844 Stereo-EEG is a minimally invasive technique used to localize the origin of epileptic activity (the epileptogenic zone) in patients with drug-resistant epilepsy. However, current stereo-EEG trajectory planning methods are agnostic to the spatial recording sensitivity of implanted electrodes. In this study, we used image-based patient-specific computational models to design optimized stereo-EEG electrode configurations. Patient-specific optimized electrode configurations exhibited substantially higher recording sensitivity than clinically implanted configurations, and this may lead to a more accurate delineation of the epileptogenic zone. The optimized configurations also achieved equally good or better recording sensitivity with fewer electrodes compared with clinically implanted configurations, and this may reduce the risk for complications, including intracranial hemorrhage. This approach improves localization of the epileptogenic zone by transforming the clinical use of stereo-EEG from a discrete ad hoc sampling to an intelligent mapping of the regions of interest.